AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority.

AlbionVC

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential.  The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companies include tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Industrifonden

Investment AB Spiltan is a Swedish venture capital and private equity firm. The company, which is based in Stockholm, provides multi stage financing to businesses based within Sweden. The company will invest between SEK1 million ($125,000) and SEK10 million ($1.25 million), with a preferred investment amount of SEK2 million to SEK4 million ($240,000 to $490,000). Potential portfolio companies may come from any sector of industry, as it is more important that the business is a viable investment opportunity. Also important is that the management team is committed and has a strong track record. Businesses will be able to leverage the extensive network of angels and other relevant professionals who can contribute expertise for the development of the portfolio company. AB Spiltan will invest roughly 60% of its capital in private companies and the remaining 40% in firms that have already been listed. Private portfolios will need to demonstrate that there will be realistic opportunity for Spiltan to exit within three to five years. Most of the investments in public companies are done through affiliates such as Health Cap and Procuritas.

Investment AB Spiltan

Founded in 2015, dRx Capital is Novartis' Digital Health Venture Fund investing in entrepreneurs transforming healthcare through data and digital technology. The fund invests in technology platforms improving access to healthcare and reimagining the practice of medicine, with a focus on AI & ML, big data, R&D optimization, patient care, and pharma supply chain and commercialization.

dRx Capital

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.

Amino Collective

KAYA evolved from Enern Investments - a regional financial group formed in Prague in 2010 that grew alongside the CEE ecosystem across clean energy, tech, real estate, and other activities. Ten years and €500m AUM later, Enern remains a holding for diverse investments while KAYA is conceived as a separate, focused successor of Enern Tech for all things venture capital, with 40+ investments and latest fund of €90.

KAYA

HV will act as an instrument of strategic growth in broadening Hikma’s offerings; it will allow Hikma to tap into opportunities in the growing digital health space.HV will invest in companies where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.We will invest in companies at all stages of development, including start-ups, spinouts, and consortia investments.Our initial investment size is up to $5 million per round. HV will look at global opportunities but with a focus on the US and the Middle East & Africa (MEA). We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.

Hikma Ventures

NuvoAir

NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient's journey is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes.

NuvoAir is a specialized chronic care platform focused on virtual respiratory care. Its FDA-approved and CE-marked NuvoAir Home platform combines connected devices with care coordination services to enable patients and their healthcare providers to manage complex chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

NuvoAir Medical Partners with Privia Medical Group — Georgia to Help Transform Cardiopulmonary Care with Virtual ...

NuvoAir is a specialized chronic care platform focused on virtual respiratory care. Its FDA-approved and CE-marked NuvoAir Home platform combines connected devices with care coordination services to enable patients and their healthcare providers to manage complex chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.&nbsp;Its remote monitoring technology includes a proprietary spirometer (Air Next) and an inhaler (Aos) to offer personalized clinical insights to physicians based on the real-time data collected. It also includes data from NuvoAir Cough, a mobile app that assesses changes in nighttime coughing.&nbsp;Patients have access to personalized digital disease management content, including live classes, on-demand breathing exercises, and lifestyle tips, to better manage their symptoms and improve lung function.In addition, NuvoAir has developed a decentralized clinical trial platform, enabling remote data collection from patients' homes.Key customers and partnershipsThe company operates a B2B2C business model, partnering with health plans, pharmaceutical companies and healthcare systems, such as Roche, Novartis, and National Health Service.In April 2024, the company partnered with Privia Medical to provide cardiopulmonary care for patients throughout the state of Georgia.&nbsp;Funding and financialsIn January 2022, it raised an additional USD 11 million in a Series A funding round led by Hikma Ventures. The funds were used to launch new products and services, expand the platform more rapidly in the US and Europe, and support partnerships for decentralized clinical trials worldwide.NuvoAir says it experienced 500% growth in Q1 2021 due to the Covid-19 pandemic.

NuvoAir is a specialized chronic care platform focused on virtual respiratory care. Its FDA-approved and CE-marked NuvoAir Home platform combines connected devices with care coordination services to enable patients and their healthcare providers to manage complex chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.Its remote monitoring technology includes a proprietary spirometer (Air Next) and an inhaler (Aos) to offer personalized clinical insights to physicians based on the real-time data collected. It also includes data from NuvoAir Cough, a mobile app that assesses changes in nighttime coughing.Patients have access to personalized digital disease management content, including live classes, on-demand breathing exercises, and lifestyle tips, to better manage their symptoms and improve lung function.In addition, NuvoAir has developed a decentralized clinical trial platform, enabling remote data collection from patients' homes.Key customers and partnershipsThe company operates a B2B2C business model, partnering with health plans, pharmaceutical companies and healthcare systems, such as Roche, Novartis, and National Health Service.In April 2024, the company partnered with Privia Medical to provide cardiopulmonary care for patients throughout the state of Georgia.Funding and financialsIn January 2022, it raised an additional USD 11 million in a Series A funding round led by Hikma Ventures. The funds were used to launch new products and services, expand the platform more rapidly in the US and Europe, and support partnerships for decentralized clinical trials worldwide.NuvoAir says it experienced 500% growth in Q1 2021 due to the Covid-19 pandemic.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

NuvoAir

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless